These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20884717)

  • 21. A wolf in sheep's clothing: enteropathy associated T-cell lymphoma involving a nasal polyp masquerading as primary mucosal CD30-positive T-cell lymphoproliferative disorder.
    Attygalle AD; Vroobel KM; Madej E; Tzioni MM; Zhang C; Chen Z; Ribeiro S; Calvachini S; Sharma B; Alexander EJ; Wotherspoon AC; Du MQ
    Histopathology; 2024 Jun; 84(7):1238-1241. PubMed ID: 38383998
    [No Abstract]   [Full Text] [Related]  

  • 22. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin.
    DeCoteau JF; Butmarc JR; Kinney MC; Kadin ME
    Blood; 1996 Apr; 87(8):3437-41. PubMed ID: 8605362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD30+ T-cell lymphoproliferative disorders.
    Martin JM; Wu H; Barta SK
    Chin Clin Oncol; 2019 Feb; 8(1):4. PubMed ID: 30525751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes of rare patients with a primary cutaneous CD30+ lymphoproliferative disorder developing extracutaneous disease.
    Melchers RC; Willemze R; Vermaat JSP; Jansen PM; Daniëls LA; Putter H; Bekkenk MW; de Haas ERM; Horvath B; van Rossum MM; Sanders CJG; Veraart JCJM; Vermeer MH; Quint KD
    Blood; 2020 Mar; 135(10):769-773. PubMed ID: 31977038
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunohistochemical analysis of CD30-positive lymphoproliferative disorders for expression of CD95 and CD95L.
    Sigel JE; Hsi ED
    Mod Pathol; 2000 Apr; 13(4):446-51. PubMed ID: 10786813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The spectrum of CD30+ T cell lymphoproliferative disorders in the skin.
    Kartan S; Johnson WT; Sokol K; Alpdogan O; Gru AA; Nikbakht N; Porcu P
    Chin Clin Oncol; 2019 Feb; 8(1):3. PubMed ID: 30691273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases.
    Vergier B; Beylot-Barry M; Pulford K; Michel P; Bosq J; de Muret A; Beylot C; Delaunay MM; Avril MF; Dalac S; Bodemer C; Joly P; Groppi A; de Mascarel A; Bagot M; Mason DY; Wechsler J; Merlio JP
    Am J Surg Pathol; 1998 Oct; 22(10):1192-202. PubMed ID: 9777981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Posttransplant CD30 (Ki-1)-positive anaplastic large cell lymphoma. Report of a case with presentation as a pleural effusion.
    Jiménez-Heffernan JA; Viguer JM; Vicandi B; Jiménez-Yuste V; Palacios J; Escuin F; Gamallo C
    Acta Cytol; 1997; 41(5):1519-24. PubMed ID: 9305394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?
    Collins K; Gu J; Aung PP; Nagarajan P; Curry JL; Huen A; Ivan D; Prieto VG; Tetzlaff MT; Duvic M; Miranda RN; Vega F; Torres-Cabala CA
    Virchows Arch; 2021 Aug; 479(2):377-383. PubMed ID: 33604757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The t(2;5)-associated p80 NPM/ALK fusion protein in nodal and cutaneous CD30+ lymphoproliferative disorders.
    Su LD; Schnitzer B; Ross CW; Vasef M; Mori S; Shiota M; Mason DY; Pulford K; Headington JT; Singleton TP
    J Cutan Pathol; 1997 Nov; 24(10):597-603. PubMed ID: 9449486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment.
    Willemze R; Beljaards RC
    J Am Acad Dermatol; 1993 Jun; 28(6):973-80. PubMed ID: 8388410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-dose total skin electron beam therapy for refractory cutaneous CD30 positive lymphoproliferative disorders.
    Panjwani N; Yoo CH; Wang E; Khodadoust MS; Kim YH; Hoppe RT; Hiniker SM
    J Dermatolog Treat; 2021 Feb; 32(1):101-103. PubMed ID: 31179774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder.
    Mallet V; Bruneau J; Zuber J; Alanio C; Leclerc-Mercier S; Roque-Afonso AM; Kraft ARM; Couronné L; Roulot D; Wedemeyer H; Albert ML; Hillon P; Laroche L; Pol S; Hermine O
    J Hepatol; 2017 Dec; 67(6):1334-1339. PubMed ID: 28860025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complete remission of CD30-positive diffuse large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin.
    Hill BT; Tubbs RR; Smith MR
    Leuk Lymphoma; 2015 May; 56(5):1552-3. PubMed ID: 24717110
    [No Abstract]   [Full Text] [Related]  

  • 35. Analysis of immunoglobulin and T cell receptor genes. Part II: Possibilities and limitations in the diagnosis and management of lymphoproliferative diseases and related disorders.
    van Dongen JJ; Wolvers-Tettero IL
    Clin Chim Acta; 1991 Apr; 198(1-2):93-174. PubMed ID: 1863986
    [No Abstract]   [Full Text] [Related]  

  • 36. Lymphoproliferative disease of granular lymphocytes.
    Kugelman LC; Smith BR; Buckley P; Katz ME; Edelson RL
    J Am Acad Dermatol; 1995 May; 32(5 Pt 2):829-33. PubMed ID: 7722038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Primary cutaneous CD30-positive T-cell lymphoproliferative disorders:report of a case].
    Liu MP; Yang WX; Feng JL; Xu J
    Zhonghua Bing Li Xue Za Zhi; 2021 Jun; 50(6):673-675. PubMed ID: 34078062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin.
    Gattei V; Degan M; Gloghini A; De Iuliis A; Improta S; Rossi FM; Aldinucci D; Perin V; Serraino D; Babare R; Zagonel V; Gruss HJ; Carbone A; Pinto A
    Blood; 1997 Mar; 89(6):2048-59. PubMed ID: 9058727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pityriasis lichenoides of childhood with atypical CD30-positive cells and clonal T-cell receptor gene rearrangements.
    Panhans A; Bodemer C; Macinthyre E; Fraitag S; Paul C; de Prost Y
    J Am Acad Dermatol; 1996 Sep; 35(3 Pt 1):489-90. PubMed ID: 8784298
    [No Abstract]   [Full Text] [Related]  

  • 40. CD30+ lymphoproliferative disorders of the skin: still an open question.
    Alaibac M; Zarian H; Russo I; Peserico A
    G Ital Dermatol Venereol; 2012 Dec; 147(6):545-52. PubMed ID: 23149700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.